HEERLEN, The Netherlands, April 6, 2005 (PRIMEZONE) -- At today's Annual General Meeting, starting at 14.00 hrs, Peter Elverding, Chairman of the DSM Managing Board, will give a trading update on Q1 2005.
DSM confirms its outlook statement, made in February, that its Q1 2005 operating profit will be substantially higher than in Q1 2004, but revises its related indication upwards, from a previously expected level of 20% to a level which is about 40% higher than in Q1 2004 (which stood at EUR 131 million; IFRS-based and before exceptional items).
This trading update reflects stronger than expected market conditions in Performance Materials and Industrial Chemicals and a continued good performance of DSM Nutritional Products, whereas the dollar and raw material prices have remained unfavorable.
DSM will publish its first quarter results on 27 April 2005.
DSM
DSM is active worldwide in life science products, performance materials and industrial chemicals. The group develops, produces and markets innovative products and services that are designed to raise the quality of life. DSM's products are used in a wide range of end-use markets and applications, including human and animal nutrition and health, cosmetics, pharmaceuticals, the automotive industry, coatings, the construction industry and the electrics & electronics market. The group has annual sales of around EUR 8 billion and employs about 24,000 people worldwide. DSM is a leading world player in many of the markets in which it operates and has plants and facilities on every continent. The company's head office is in the Netherlands. For more information on DSM, please visit www.dsm.com.
For more information: DSM Corporate Communications Medard Schoenmaeckers tel. +31 (0) 45 5782421 fax +31 (0) 45 5740680 e-mail media.relations@dsm.com DSM Investor Relations Dries Ausems tel. +31 (0) 45 5782864 fax +31 (0) 45 5782595 e-mail investor.relations@dsm.com
To view this release as a .pdf visit the following link: